We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cellceutix Receives Notice of Acceptance for Phase 1 Clinical Trial
News

Cellceutix Receives Notice of Acceptance for Phase 1 Clinical Trial

Cellceutix Receives Notice of Acceptance for Phase 1 Clinical Trial
News

Cellceutix Receives Notice of Acceptance for Phase 1 Clinical Trial

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cellceutix Receives Notice of Acceptance for Phase 1 Clinical Trial"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cellceutix Corporation reports that it has received notice of acceptance for a clinical trial of Kevetrin™, Cellceutix's flagship compound as an indication for drug-resistant cancers, to be conducted at one of the world's most prominent cancer centers.

"I am pleased to announce this significant milestone in the development of Kevetrin," commented Leo Ehrlich, CEO of Cellceutix.

Ehrlich continued, "Our research to date on Kevetrin™ has been stellar and the approval to conduct our clinical trials at what many believe to be the world's foremost cancer research center adds a great deal of validation to our beliefs that Kevetrin™ could be one of the leading cancer compounds known at this time. Additional details will be coming upon finalization of review and signed contracts."

Advertisement